Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
The Dow then and now: original, current members of index

NEW YORK (AP) — S&P Dow Jones Indices announced Tuesday that General Electric would be replaced in the Dow Jones industrial average by Walgreens Boots Alliance.

CVX : 124.52 (-0.81%)
JNJ : 121.92 (-0.53%)
PG : 75.75 (-0.76%)
PFE : 36.38 (+0.44%)
BA : 341.33 (+0.06%)
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

NEW BRUNSWICK, N.J. , June 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , July 17, to review second-quarter...

JNJ : 121.92 (-0.53%)
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results. Alex Gorsky, Chairman and Chief Executive Officer...

JNJ : 121.92 (-0.53%)
IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack Damage

IPS HEART, resident of Johnson & Johnson Innovation, JLABS is pioneering the use of IPS cellular therapy for the replacement of heart tissue after heart attack, heart failure and duchenne...

JNJ : 121.92 (-0.53%)
Reinvigorated Healthcare Industry Being Boosted by Quantitative Advancements and Device Breakthroughs

MarketNewsUpdates.com News Commentary

FBIO : 3.10 (+0.65%)
ZENO : 0.4300 (-21.97%)
JNJ : 121.92 (-0.53%)
BEAT : 46.80 (+2.52%)
IRTC : 82.06 (+0.33%)
Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe

--A second study shows esketamine was generally well tolerated with no new safety signals

JNJ : 121.92 (-0.53%)
Asian stocks tumble after new Trump tariff threat

BEIJING (AP) — Asian stocks tumbled Tuesday after U.S. President Donald Trump escalated a dispute with Beijing over technology policy by threatening a tariff hike on additional Chinese goods.

JNJ : 121.92 (-0.53%)
PG : 75.75 (-0.76%)
CL : 63.58 (-0.66%)
Markets Right Now: Stocks look to recover from early skid

NEW YORK (AP) — The latest on developments in financial markets (all times local):

CAT : 142.29 (-0.70%)
JNJ : 121.92 (-0.53%)
Johnson&Johnson Set to Possibly Rebound After Yesterday's Selloff of 1.45%

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $120.25 to a high of $121.81. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $121.24...

JNJ : 121.92 (-0.53%)
After Yesterday's Decline of 1.45%, Johnson&Johnson Offers Investors Better Value

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $120.25 to a high of $121.81. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $121.24...

JNJ : 121.92 (-0.53%)
Johnson&Johnson (JNJ) Approaches New Downside Target of $120.70

Shares of Johnson&Johnson (NYSE:JNJ) have bearishly opened below the pivot of $122.19 today and have reached the first support level of $121.66. Investors may be interested in a cross of the next downside...

JNJ : 121.92 (-0.53%)
FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio

SANTA ANA, Calif. , June 18, 2018 /PRNewswire/ -- Johnson & Johnson Vision announced today the U.S. Food and Drug Administration (FDA) approval of the iDESIGN Refractive Studio, making it the only system...

JNJ : 121.92 (-0.53%)
FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio

Johnson & Johnson Vision announced today the U.S. Food and Drug Administration (FDA) approval of the iDESIGN Refractive Studio, making it the only system to use topography-integrated, wavefront-guided...

JNJ : 121.92 (-0.53%)
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

OFIX : 60.19 (-0.40%)
SYK : 170.59 (+0.51%)
OSUR : 17.65 (-0.34%)
HSIC : 72.60 (+0.28%)
VAR : 120.86 (-0.19%)
BSX : 32.35 (+1.35%)
ABMD : 449.85 (+2.32%)
NXTM : 28.26 (-0.42%)
JNJ : 121.92 (-0.53%)
EGRX : 75.90 (+0.78%)
INSY : 7.99 (+1.52%)
MNK : 20.06 (-0.59%)
TGTX : 14.10 (+1.08%)
ABT : 62.17 (-0.27%)
SRDX : 55.00 (+0.36%)
BAX : 73.76 (-0.55%)
MDT : 85.98 (-0.73%)
ISRG : 491.05 (+0.50%)
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen

MYL : 38.76 (+0.08%)
JNJ : 121.92 (-0.53%)
PFE : 36.38 (+0.44%)
GSK : 40.93 (-0.27%)
Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod

The Dow traversed a tough week, suffering losses for three consecutive sessions.

VZ : 48.03 (-0.97%)
JPM : 108.11 (+0.52%)
JNJ : 121.92 (-0.53%)
MRK : 60.86 (-0.28%)
CAT : 142.29 (-0.70%)
XOM : 80.40 (-0.37%)
PG : 75.75 (-0.76%)
DIS : 107.37 (+1.20%)
BA : 341.33 (+0.06%)
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

CVS : 70.77 (-0.23%)
CI : 174.58 (+0.70%)
JNJ : 121.92 (-0.53%)
BDX : 230.75 (+0.32%)
Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed.

BOSTON , June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking...

JNJ : 121.92 (-0.53%)
Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed.

Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation for their injuries. According to...

JNJ : 121.92 (-0.53%)
Hillenbrand Announces New Head of Investor Relations

Hillenbrand, Inc. (NYSE: HI) announced that Richard A. Dudley has been appointed as its new leader of investor relations.

HI : 47.50 (+0.64%)
JNJ : 121.92 (-0.53%)

Van Meerten Stock Picks

5 Great Large Caps
This morning I wanted to find 5 Large Cap stocks that had performed well over the last year and still appeared to have some juice left in them.
ABMD +10.21 , NFLX +8.80 , VLO -0.88 , RL -0.38 , ALGN +0.57
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures are trading 1 to 2 cents higher at the moment. They closed Tuesday with nearby contracts 1 to 2 1/4 cent in the red, coming back from sharp early morning losses. December posted a new life of contract low at $3.60 on Tuesday, while closi...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar